Viscosupplementation is one of the prominent treatments available for Osteoarthritis; a musculoskeletal disability becoming increasingly common among the middle ages and elderly population around the world. The treatment procedure contains injecting a thick fluid, Hyaluronic Acid directly in the affected area like knee, shoulder or hip; and a course of single or multiple injections. The Hyaluronic Acid is found in the Synovial Fluid around the joint that acts as a lubricating agent and improves the mobility of joints; it also acts as a shock absorber due to its viscosity.
This degenerative joint disease mainly affecting the articular cartilage is classified into two: Primary Osteoarthritis, due to aging and natural wear and tear of joints; and, Secondary Osteoarthritis, due to an accident or obesity in early age. Around 9.6% men and 18% women globally, are above the age of 60 and suffers from symptoms of Osteoarthritis, according to the WHO. The steady growth rate of 6.5% and low mortality rate across the globe has given way to a large and growing geriatric population vulnerable to Osteoarthritis has increased the demand for its treatment. The rising obese population around the world, increasing patient awareness towards new drugs and devices for treatment; and a demand for new, innovative and more economical treatment procedures that are less invasive than the surgical procedures, like the knee replacement surgery, are some of the factors that are driving the growth of Viscosupplementation market.
The global market for Viscosupplementation is on the rise with U.S leading the way for high awareness, high product demand and ready acceptance of high priced products. This is also driven by the government policy, rise in medical infrastructure and reimbursement policies. The Asia-Pacific region has ample of scope of becoming the largest market, with Japan as the second largest Viscosupplementation market. The large geriatric pool of population from rural undeveloped South Asian economies, especially China are now getting access to new and advanced medical treatments, making it a big for Viscosupplementation in near future. The European market has become stagnant and is growing very slowly, as it has been hit by the recession, and have difficult reimbursement policies in many countries.
The Viscosupplementation market faces many challenges as cost-effectiveness, safety of the patients from unwanted side-effects and other allergies has to be looked into, and may have a chance to vary for different individuals making it more difficult for the market players to have a product that is safe and commercially and economically feasible. There is a considerable reduction of cost from invasive surgical procedures to Viscosupplementation, and it also reduces various other risks anaesthetic reactions; opening a number of new avenues for the people and the market.
This degenerative joint disease mainly affecting the articular cartilage is classified into two: Primary Osteoarthritis, due to aging and natural wear and tear of joints; and, Secondary Osteoarthritis, due to an accident or obesity in early age. Around 9.6% men and 18% women globally, are above the age of 60 and suffers from symptoms of Osteoarthritis, according to the WHO. The steady growth rate of 6.5% and low mortality rate across the globe has given way to a large and growing geriatric population vulnerable to Osteoarthritis has increased the demand for its treatment. The rising obese population around the world, increasing patient awareness towards new drugs and devices for treatment; and a demand for new, innovative and more economical treatment procedures that are less invasive than the surgical procedures, like the knee replacement surgery, are some of the factors that are driving the growth of Viscosupplementation market.
The global market for Viscosupplementation is on the rise with U.S leading the way for high awareness, high product demand and ready acceptance of high priced products. This is also driven by the government policy, rise in medical infrastructure and reimbursement policies. The Asia-Pacific region has ample of scope of becoming the largest market, with Japan as the second largest Viscosupplementation market. The large geriatric pool of population from rural undeveloped South Asian economies, especially China are now getting access to new and advanced medical treatments, making it a big for Viscosupplementation in near future. The European market has become stagnant and is growing very slowly, as it has been hit by the recession, and have difficult reimbursement policies in many countries.
The Viscosupplementation market faces many challenges as cost-effectiveness, safety of the patients from unwanted side-effects and other allergies has to be looked into, and may have a chance to vary for different individuals making it more difficult for the market players to have a product that is safe and commercially and economically feasible. There is a considerable reduction of cost from invasive surgical procedures to Viscosupplementation, and it also reduces various other risks anaesthetic reactions; opening a number of new avenues for the people and the market.